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OBJECTIVE We sought to compare the acute hemodynamic effects of inhaled nitric oxide (NO) and
aerosolized iloprost in primary pulmonary hypertension (PPH).
BACKGROUND Inhalation of the stable prostacyclin analogue iloprost has recently been described as a novel
therapeutic strategy for PPH and may offer an alternative to continuous intravenous infusion
of prostacyclin or inhalation of NO.
METHODS During right heart catheterization, 35 patients with PPH sequentially inhaled 40 ppm of NO
and 14 to 17 mg of iloprost, and the effects on hemodynamics and blood gases were
monitored.
RESULTS Both NO and iloprost caused significant increases in cardiac output, mixed-venous oxygen
saturation and stroke volume as well as significant decreases in pulmonary artery pressure and
pulmonary vascular resistance, whereas only inhaled iloprost significantly increased the
arterial PO2 (p 5 0.01). Compared with inhaled NO, aerosolized iloprost was more effective
in reducing pulmonary artery pressure (28.3 6 7.5 mm Hg vs. 24.3 6 8.8 mm Hg; p 5
0.0001) and the pulmonary vascular resistance (2447 6 340 dyneszszcm25 vs. 2183 6 305
dynezszcm25; p , 0.0001). Furthermore, aerosolized iloprost caused a significantly greater
increase of the cardiac output compared with NO (10.7 6 0.6 liter/min vs. 10.3 6 0.4
liter/min; p 5 0.0002) and had a more pronounced effect on the mixed-venous oxygen
saturation (p 5 0.003).
CONCLUSIONS During acute drug testing, aerosolized iloprost was more potent than inhaled NO as a
pulmonary vasodilator in PPH at the doses used in this study. (J Am Coll Cardiol 2000;35:
176–82) © 1999 by the American College of Cardiology
The most significant improvement in the treatment of
severe primary pulmonary hypertension (PPH) in recent
years has been the introduction of continuous intravenous
prostacyclin (PGI2) infusion, which has been shown to
improve exercise tolerance and survival (1–7). This form of
treatment, however, has major drawbacks. Intravenous
PGI2 can cause substantial side effects such as systemic
hypotension, nausea, vomiting and diarrhea, headache and a
worsening of gas exchange (4,5,8). Moreover, the long-term
therapeutic application of PGI2 requires a permanent cen-
tral venous catheter, which may result in thrombotic or
infectious complications. Furthermore, the continuous in-
travenous administration of PGI2 leads to tachyphylaxis and
therefore requires permanent dose escalation, and there is a
substantial risk of severe rebound phenomena when the
infusion is interrupted (5).
An alternative drug recently proposed for the treatment
of pulmonary hypertension is nitric oxide (NO) (9–11).
Acute vasoreagibility testing with inhaled NO has been
introduced as a safe means to identify patients who can be
expected to benefit from long-term treatment with oral
vasodilators (10,12). In addition, the identification of pa-
tients who exhibit a marked reactivity of the pulmonary
vascular bed is a valuable prognostic marker (13). For
theoretical reasons, inhaled NO offers several advantages
over intravenous PGI2 for long-term treatment of PPH.
Nitric oxide is a potent and selective pulmonary vasodilator
with virtually no systemic side effects, due to rapid inacti-
vation by hemoglobin binding after entering the vascular
space. In addition, unlike systemic vasodilators, inhaled NO
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acts selectively in ventilated areas of the lung, thus causing
redistribution of blood flow from shunt areas to ventilated
areas (14). These factors may be especially relevant for
treatment of advanced right heart failure in which any
systemic vasodilator carries the risk of worsening hypoxia
and hypotension. However, because of its short half-life,
NO has to be administered continuously, and even brief
interruptions of the supply may cause dangerous rebound
pulmonary hypertension (15). In addition, to our knowl-
edge, there are currently no controlled data suggesting a
long-term benefit from inhaled NO for patients with PPH.
Recently, Olschewski et al. (16) described the use of
aerosolized iloprost for severe pulmonary hypertension.
Iloprost is a carbacyclin analogue of PGI2 that has a plasma
half-life of 20 to 30 min (17,18). When inhaled, iloprost
seems to cause preferential pulmonary vasodilation that lasts
for about 1 to 2 h (16). This form of treatment appears to
be promising because it may combine the beneficial long-
term effects of continuous intravenous PGI2 with the
advantages of inhaled NO without the problems of contin-
uous intravenous administration.
Unlike NO, inhaled iloprost may also act in the systemic
circulation, as the molecule will not be rapidly inactivated in
the pulmonary vascular bed. It is currently not known to
what extent systemic effects might add to the local pulmo-
nary effects. To further evaluate the pharmacodynamic
profile of aerosolized iloprost, we compared the acute
hemodynamic effects of inhaled NO and aerosolized ilo-
prost in patients with PPH.
METHODS
Patient population. This investigation was part of a Ger-
man multicenter trial initiated to evaluate the efficacy of
aerosolized iloprost in severe pulmonary hypertension. In
this study, only patients were included who fulfilled the
diagnostic criteria of the National Institutes of Health
registry for PPH (19).
Patients were excluded from the study when they suffered
from significant coagulopathy, when they had severe airway
obstruction, when they suffered from a coronary or cerebro-
vascular event within three months before the study or when
there was significant impairment of liver and kidney func-
tion. Any concomitant medication except for anticoagula-
tion was kept unchanged. Treatment with oral anticoagu-
lants was stopped until the international normalized ratio
was lower than 1.5, and all patients received intravenous
heparin (400 to 800 U/h) while the catheters were inserted.
The study protocol was reviewed and approved by the
institutional ethical committees of all participating centers,
and all patients provided written informed consent before
entering the study.
Hemodynamic monitoring. For the purpose of this study,
the patients were admitted to an intensive care unit. An 8F
introducer sheet was placed into the right or left internal
jugular vein and a triple lumen 7.5F flow-directed Swan-
Ganz-catheter (Baxter, Edwards, California) was advanced
into the pulmonary artery. Correct positioning of the
catheter was verified by chest X-ray or fluoroscopy. A 5F
Teflon catheter was inserted into a femoral artery. Trans-
ducers were positioned at the midaxillary line and zeroed at
atmospheric pressure. Systolic, diastolic and mean pulmo-
nary and systemic arterial pressures as well as the right atrial
pressure were monitored continuously, and the pulmonary
capillary wedge pressure (PCWP) was determined at base-
line and at the end of each evaluation period. The cardiac
output (CO) was measured in triplicate by the thermodilu-
tion technique (Cardiac Output Computer; Baxter, Ed-
wards, California) with ice-cold isotonic sodium chloride
solution, and the cardiac index was calculated by dividing
the CO through the body surface area. The pulmonary
vascular resistance was calculated as mean pulmonary artery
pressure, 2 PCWP (PAPmean 2 PCWP) p 80/CO. The
systemic vascular resistance was calculated as mean systemic
blood pressure 2 right atrial pressure (SAP 2 RAP) p
80/CO. The heart rate and the transcutaneous arterial
oxygen saturation were monitored continuously.
Blood samples. Arterial and mixed-venous blood samples
were obtained simultaneously for determination of PO2,
PCO2, pH, base excess and SO2 (ABL 520, Radiometer,
Copenhagen).
Vasodilator protocol. After insertion of the catheters, the
patients were allowed to rest for at least 15 min. The
patients were breathing through an inhalation device (rain-
drop nebulizer) that had been developed for the application
of iloprost (Iloneb, Nebutec, Elsenfeld, Germany). When
the arterial oxygen saturation was ,90%, supplemental
oxygen was added to the inhalation device until the oxygen
saturation was .90%, and the oxygen flow was kept
constant throughout the study. After the baseline variables
had been obtained (baseline 1), NO was added to the
inspiratory limb of the device until an expiratory concentra-
tion of 40 ppm was reached. The NO concentration was
measured using the electrochemical technique (MicroGas
Nitric Oxide Monitor, Med In, Munich, Germany). After
15 min of inhaling NO at 40 ppm, a complete evaluation of
hemodynamics and blood gases was performed. Thereafter,
NO was discontinued. Thirty minutes later, another set of
baseline hemodynamics was recorded (baseline 2), and the
inhalation of iloprost (Ilomedin, Schering AG, Berlin,
Abbreviations and Acronyms
CO 5 cardiac output
NO 5 nitric oxide
NYHA 5 New York Heart Association
PCWP 5 pulmonary capillary wedge pressure
PGI2 5 prostacyclin
PPH 5 primary pulmonary hypertension
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Germany) was started. Fifty micrograms of iloprost was
diluted in 5 ml of isotone saline solution and nebulized in
the device described above for 15 min, which resulted in an
aerosolized dose between 14 and 17 mg. This approach has
been shown to provide a safe and effective means for delivery
of iloprost aerosol (16). Complete sets of hemodynamic
measurements and blood gases were performed before
inhalation, in the last minute of the inhalation period and
every 15 min thereafter for up to 1 h.
Statistical analysis. The results are expressed as mean
6SD (range) unless indicated otherwise. The individual
preinhalation and postinhalation variables were compared
by means of the Wilcoxon signed-rank test. This test was
also applied to compare the pre-post differences of NO
inhalation and iloprost inhalation (both measured immedi-
ately before and at the end of the inhalation period). The
calculated significance levels were used as the criterion to
state differences between the inhalative agents (explorative
strategy). The Friedman test was employed to test for global
changes from baseline during repeated measurements over
1 h after inhalation. To further settle for significant differ-
ences at different time points (repeated measurements), the
upper 95% confidence limits for medians were calculated,
and a significant effect was assumed when the 95% confi-
dence interval was below the baseline value. All tests were
two-sided. Significance was set at p , 0.05.
RESULTS
Study population. We studied 35 patients, 19 women and
16 men with PPH. The mean age was 46 6 13 years (range,
20 to 76 years). Six patients were New York Heart Associ-
ation (NYHA) class II, 18 patients were NYHA class III
and 11 patients were NYHA class IV. Fifteen patients were
receiving low-dose calcium-channel blockers (maximum
daily dose of 40 mg nifedipine or 5 mg felodipine). The
baseline hemodynamic variables are shown in Table 1.
Hemodynamic responses. The hemodynamic parameters
and the oxygenation status at baseline and at the end of
inhalation with NO and iloprost are shown in Table 1 and
in Fig. 1A to C. During inhalation of NO, the mean
pulmonary arterial pressure declined by 4.3 6 8.8 mm Hg
(range, 111 to 227 mm Hg; p 5 0.008 vs. baseline),
whereas the systemic arterial pressure and the systemic
vascular resistance remained unchanged. The CO increased
by 0.3 6 0.4 liter/min (range, 20.37 to 11.11 liter/min;
p 5 0.001 vs. baseline), and the stroke volume increased by
4.2 6 8.2 ml (range, 215.4 to 126.4 ml; p 5 0.009 vs.
baseline). The right atrial pressure fell by 1.1 6 2.1 mm Hg
(range, 26 to 12 mm Hg; p 5 0.004 vs. baseline). The
mixed-venous oxygen saturation rose by 2.5% 6 6.7%
(range, 212% to 119.9%; p 5 0.06 vs. baseline). The
pulmonary vascular resistance declined by 183 6 305 dynes
(range, 21,258 dynes to 1318 dynes; p 5 0.0006 vs.
baseline). The arterial PO2 was minimally affected during
inhalation of NO (11.8 6 14.1 mm Hg; p 5 0.84).
Aerosolized iloprost caused a decline of the mean
pulmonary arterial pressure by 28.3 6 7.5 mm Hg
(range, 233 to 60 mm Hg; p , 0.001 vs. baseline).
There was a statistically significant difference between
the effects of NO and iloprost on the mean pulmonary
artery pressure (p 5 0.0001). Furthermore, iloprost
caused an increase of the CO by 0.7 6 0.6 liter/min
(range, 20.1 to 13.3 liter/min). This was also statisti-
cally significant when tested against baseline (p ,










HR (beats/min) 84 6 17 83 6 17 87 6 16 86 6 17
SAPmean (mm Hg) 93 6 15 94 6 15 89 6 15 86 6 13*†
PAPmean (mm Hg) 59 6 11 55 6 15* 60 6 11 52 6 13*†
RAP (mm Hg) 8 6 6 7 6 6* 8 6 6 7 6 5*
PCWP (mm Hg) 7 6 3 6 6 3 7 6 3 7 6 3
CO (liter/min) 3.4 6 1.1 3.7 6 1.2* 3.5 6 1.2 4.2 6 1.2*†
CI (liter/min/m2) 2.0 6 0.7 2.1 6 0.7* 2.0 6 0.7 2.4 6 0.7*†
SV (ml) 43 6 18 47 6 19* 42 6 18 51 6 16*†
SVR (dyneszszcm25) 2,127 6 670 2,024 6 642 2,017 6 741 1,597 6 519*†
PVR (dyneszszcm25) 1,342 6 518 1,159 6 587* 1,367 6 492 920 6 387*†
PaO2 (mm Hg) 66 6 14 68 6 15 66 6 12 73 6 18*†
SaO2 (%) 90 6 12 92 6 6 91 6 5 94 6 4*
SvO2 (%) 58 6 14 60 6 13* 59 6 15 66 6 13*†
CI 5 cardiac index; CO 5 cardiac output; HR 5 heart rate; NO 5 nitric oxide; PaO2 5 arterial oxygen tension; PAP 5
pulmonary arterial pressure; PCWP 5 pulmonary capillary wedge pressure; PVR 5 pulmonary vascular resistance; RAP 5 right
atrial pressure; SaO2 5 arterial oxygen saturation; SAP 5 systemic arterial blood pressure; SV 5 stroke volume; SvO2 5
mixed-venous oxygen saturation; SVR 5 systemic vacular resistance.
*p , 0.05 for NO vs. baseline 1 and iloprost versus baseline 2, respectively.
†p , 0.05 for iloprost vs. NO.
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0.0001) as well as against the effects of NO (p 5 0.0002).
In addition, iloprost caused a significant increase of the
stroke volume by 8.8 6 9.5 ml (range, 212.2 to 138.2
ml; p , 0.0001 vs. baseline and p 5 0.005 vs. NO). The
right atrial pressure fell by 1.5 6 2.5 mm Hg (range, 29
to 13 mm Hg; p 5 0.002 vs. baseline), which was not
significantly different from the change of the right atrial
pressure during inhalation of NO. The mixed venous
oxygen saturation rose by 7.5% 6 6.5% (range, 10.4% to
29.1%; p , 0.0001 vs. baseline and p 5 0.003 vs. NO).
The pulmonary vascular resistance declined by 447 6 340
dynes (range, 242 dynes to 21,788 dynes). This differ-
ence was highly significant when compared with baseline
(p , 0.0001) and when compared with NO (p , 0.0001).
The systemic vascular resistance was also significantly reduced
by iloprost (2420 6 384 dynes; range, 199 to 21,318 dynes;
p , 0.0001 vs. baseline and p , 0.0001 vs. NO), and the
systemic arterial pressure declined by 23.5 6 7.0 mm Hg
(range, 221 to 114 mm Hg; p , 0.01 vs. baseline; p 5 0.002
vs. NO). Clinically relevant systemic hypotension (i.e., a drop
in the systolic blood pressure below 90 mm Hg) occurred in
none of our patients during inhalation of iloprost.
Furthermore, aerosolized iloprost resulted in an increase
of the arterial PO2 by 6.9 6 14.8 mm Hg (range, 215 to
162 mm Hg) that was statistically significant in comparison
to baseline (p 5 0.01) and in comparison to NO (p 5 0.02).
Heart rate and PCWP were not significantly affected by
either NO or iloprost.
Figure 1. Comparison of the effects of inhaled nitric oxide
(NO, 40 ppm for 15 min) and aerosolized iloprost (14 to
17 mg over 15 min) on pulmonary artery pressure (A), cardiac
output (B) and pulmonary vascular resistance (C) in 35
patients with primary pulmonary hypertension. Dots repre-
sent the individual responses compared to baseline, expressed
as percentage. A location below the line of identity indicates
a more pronounced effect of iloprost, while a location above
the line of identity reflects a more pronounced effect of NO.
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There was a significant correlation between the effects of
NO and iloprost on the pulmonary vascular resistance (r 5
0.63; p , 0.01) but only in four cases, the NO response was
greater or equal to the iloprost response (Fig. 1C). In
addition, inhaled NO led to a paradoxical increase of the
pulmonary vascular resistance in six of our patients (17%)
and of the pulmonary artery pressure in 10 of our patients
(29%), which did not occur with iloprost. Of the 24 patients
with a minor response to NO (defined as a pulmonary
vascular resistance decrease of ,20%), 13 patients (54%)
exhibited a significant response during inhalation of iloprost
(e.g., a decrease of the pulmonary vascular resistance by
.20%; Fig. 1C).
Time course. The effects of NO were evident within 2 to
5 min after the beginning of the inhalation and lasted only
for a couple of minutes after the supply was stopped (data
not shown). The effects of iloprost also became evident
within 2 to 5 min after the inhalation was started and
reached a maximum at cumulative doses between 14 and
17 mg, which, in our setting, were attained within 12 to
15 min. The maximum effect was maintained for 5 to
30 min and then began to wane. Sixty minutes after the end
of inhalation, there was no longer a significant change in the
pulmonary vascular resistance. The data of a subset of 20
patients for whom a complete 1-h monitoring was available
are shown in Figure 2.
Side effects. No severe complications related to catheter
testing or drug administration occurred during this study.
Inhalation of NO and of iloprost was generally well toler-
ated. No patient experienced any side effect during inhala-
tion of NO, but five patients developed minor headache and
a facial flush while inhaling iloprost. These side effects did
not lead to premature termination of the inhalation and
ceased a few minutes after the inhalation was ended. One
patient described mild jaw pain immediately after inhalation
of iloprost, which also ceased after a few minutes. Gastro-
intestinal discomfort was not observed. In addition, there
was no evidence of rebound pulmonary hypertension after
administration of NO or iloprost.
DISCUSSION
In this study, we compared the acute effects of aerosolized
iloprost and inhaled NO in patients with PPH. Notably,
iloprost caused a significantly greater decline in pulmonary
arterial pressure and pulmonary vascular resistance than
NO. In addition to its hemodynamic profile, aerosolized
iloprost, in contrast to inhaled NO, also exerted beneficial
effects on arterial oxygenation, which probably reflected the
more potent effects of iloprost on the pulmonary vascular
bed and the more pronounced increase of mixed-venous
oxygen saturation.
The more potent acute effect of iloprost on pulmonary
vascular resistance was reflected not only by a more pro-
nounced decline of pulmonary artery pressure but also by a
more prominent increase in CO when compared with NO.
Since iloprost uniformly exhibited such effects on CO, even
in patients in whom both NO and iloprost caused a similar
decline of pulmonary artery pressure, we speculate that some
degree of systemic vasodilation in response to iloprost
inhalation could have led to activation of the baroreceptor
reflex, which may have resulted in an indirect positive
inotropic effect due to increased sympathetic nerve activity.
A direct positive inotropic action of iloprost could be an
alternative explanation because a prostanoid-mediated in-
crease of cyclic AMP in cardiomyocytes has been shown to
exert positive inotropic effects in experimental models
(20,21). However, at this time, it is unclear whether PGI2
receptors are expressed on human cardiomyocytes.
Unexpectedly, NO caused an increase in pulmonary
artery pressure and pulmonary vascular resistance in 10 out
of 35 (29%) and 6 out of 35 (17%), respectively, of our
patients. This observation concurs with a report from Sitbon
et al. (10), who reported an increase of pulmonary artery
pressure and pulmonary vascular resistance in 8 out of 35
(23%) and 11 out of 35 (31%) of their patients, respectively,
while using a comparable concentration of NO. The mech-
anisms by which NO may cause an increase in pulmonary
vascular resistance remain obscure. Voelkel et al. (22) have
shown that under certain experimental circumstances, for
example, in the presence of hemolysate, NO may become a
potent pulmonary vasoconstrictor, but again, the underlying
mechanisms are still unknown. By contrast to inhaled NO,
aerosolized iloprost caused a decline in pulmonary artery
pressure and pulmonary vascular resistance in all of our
patients (except for one patient in whom the pulmonary
artery pressure remained unchanged).
The acute hemodynamic effects of aerosolized iloprost on
pulmonary artery pressure, pulmonary vascular resistance
and CO in PPH patients compared quite well with pub-
Figure 2. Time course of the effects of aerosolized iloprost on
pulmonary vascular resistance (PVR). Patients were inhaling 14 to
17 mg iloprost within 15 min and the hemodynamic variables were
measured at the indicated time points. Changes in PVR (percent)
are shown as median and upper 95% confidence limits of the
median. Asterisk indicates p , 0.05 vs. baseline.
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lished effects of acute intravenous PGI2 (4,10,16,23). How-
ever, a decline in systemic blood pressure was a potential
side effect in patients receiving intravenous PGI2, and some
patients with advanced right heart failure may not tolerate
even lowest doses of intravenous PGI2 (24). By contrast,
clinically relevant systemic hypotension was not observed in
any of our patients receiving aerosolized iloprost.
The action of aerosolized iloprost was relatively short-
lived and vanished almost completely within 1 h after
inhalation (Fig. 2). This observation was surprising with
respect to the demonstration of sustained benefits of inter-
mittent delivery of aerosolized iloprost as described by
Olschewski and coworkers (16,24). There is evidence that
the long-term effects of PGI2 might not be related simply to
vasodilation but to other, yet unknown, mechanisms affect-
ing pulmonary vascular remodeling (4,7,25,26). It seems
possible that some of these ill-defined effects of prostanoids
on the pulmonary vasculature in pulmonary hypertension do
not require continuous administration (27).
Our study has several limitations. First, NO was always
given before iloprost, and although we ensured that the
hemodynamics had returned to baseline before iloprost was
administered, we cannot fully exclude a conditioning or
priming effect of pretreatment with NO. Furthermore, the
concentration of 40 ppm NO used in our study may not
have caused maximum vasodilation in all patients. However,
recent investigations have shown that maximum effects on
pulmonary artery pressure can be achieved with NO con-
centrations between 10 and 20 ppm and that higher
concentrations of NO do not augment the vasodilatory
action (10).
In summary, aerosolized iloprost exhibited a favorable
hemodynamic response during acute drug testing in our
PPH patients: pulmonary artery pressure and pulmonary
vascular resistance decreased, CO and arterial PO2 in-
creased, and systemic blood pressure remained stable. Com-
pared with the acute effects of inhaled NO, aerosolized
iloprost—at least at the doses used in this study—was
significantly more potent in reducing pulmonary artery
pressure and pulmonary vascular resistance and also caused
a significantly greater increase in CO. Moreover, aerosol-
ized iloprost was well tolerated, and no major side effects
were observed.
APPENDIX
Members of the German PPH study group are as follows:
Werner Seeger, MD, Horst Olschewski, MD, Friedrich
Grimminger, MD, H.A. Ghofrani, MD, Thomas Schmehl,
PhD, Saskia Diehl, F. Rohlfing, Justus Liebig University
Giessen; Marius M. Hoeper, MD, Michael Hamm, MD,
Jost Niedermeyer, MD, Helmut Fabel, MD, Medizinische
Hochschule Hannover; Heinrike Wilkens, MD, Andreas
Eichler, MD, Gerd Sybrecht, MD, University of the Saar-
land, Homburg; Joerg Winkler, MD, Joachim Schauer,
MD, University of Leipzig; Mathias M. Borst, MD, F.-
Joachim Meyer, MD, Wolfgang Ku¨bler, MD, FRCP,
Ruprecht-Karls-University of Heidelberg; Friedrich Klu¨p-
pelberg, MD, Volker Schulz, MD, Thoraxklinik Heidel-
berg; M. Behr, MD, Claus Vogelmeier, MD, Klinikum
Großhadern, Munich; Heinrich Worth, University Hospi-
tal of Fu¨rth; Germany.
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